Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts ...

Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

Serum autotaxin levels are significantly elevated in patients with migraine and correlate with headache severity, ...

Preventive antimigraine therapy (PAM) should probably not be considered until the headache frequency exceeds 1 per week. PAM is associated with significant side effects and often with ...